Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial

BACKGROUND: An unmet medical need exists for patients with metastatic renal cell carcinoma (RCC) who have progressed on a vascular endothelial growth factor (VEGF)–targeted therapy plus a mammalian target of rapamycin (mTOR) inhibitor. Fibroblast growth factor (FGF) pathway activation has been propo...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Lancet Oncol
Autors principals: Motzer, Robert J, Porta, Camillo, Vogelzang, Nicholas J, Sternberg, Cora N, Szczylik, Cezary, Zolnierek, Jakub, Kollmannsberger, Christian, Rha, Sun Young, Bjarnason, Georg A, Melichar, Bohuslav, De Giorgi, Ugo, Gruenwald, Viktor, Davis, Ian D, Lee, Jae-Lyun, Esteban, Emilio, Urbanowitz, Gladys, Cai, Can, Squires, Matthew, Marker, Mahtab, Shi, Michael, Escudier, Bernard
Format: Artigo
Idioma:Inglês
Publicat: 2014
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5719485/
https://ncbi.nlm.nih.gov/pubmed/24556040
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(14)70030-0
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars